Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-80948543 + JNJ-87801493 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-80948543 | JNJ 80948543|JNJ80948543 | CD3 Antibody 99 | JNJ-80948543 is an antibody that targets an undisclosed tumor-associated antigen (TAA) and the T-cell antigen CD3, potentially resulting in activation of cytotoxic T-lymphocytes (CTLs) and tumor cell killing (NCI Drug Dictionary). | |
JNJ-87801493 | JNJ 87801493|JNJ87801493 | Limited information is currently available on JNJ-87801493 (Dec 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06139406 | Phase I | JNJ-80948543 + JNJ-87801493 JNJ-75348780 + JNJ-87801493 | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer | Recruiting | ISR | ESP | DNK | AUS | 0 |